13,916 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 13,916 shares of the company’s stock, valued at approximately $8,610,000.

Other large investors have also bought and sold shares of the company. Jacobs Levy Equity Management Inc. grew its position in Amphastar Pharmaceuticals by 44.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company’s stock worth $25,518,000 after acquiring an additional 171,642 shares during the last quarter. Walleye Capital LLC bought a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $1,833,000. Charles Schwab Investment Management Inc. boosted its position in Amphastar Pharmaceuticals by 7.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 352,378 shares of the company’s stock valued at $16,206,000 after buying an additional 24,116 shares during the last quarter. Rafferty Asset Management LLC bought a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $205,000. Finally, American Century Companies Inc. boosted its position in Amphastar Pharmaceuticals by 52.2% in the 3rd quarter. American Century Companies Inc. now owns 200,277 shares of the company’s stock valued at $9,211,000 after buying an additional 68,668 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday. JPMorgan Chase & Co. assumed coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective on the stock. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $66.00.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the sale, the director now owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the sale, the director now owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,000 shares of company stock valued at $660,860. 28.40% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Stock Down 1.3 %

NASDAQ:AMPH opened at $39.62 on Friday. Amphastar Pharmaceuticals, Inc. has a 12-month low of $35.62 and a 12-month high of $67.66. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $1.91 billion, a P/E ratio of 15.36, a P/E/G ratio of 0.96 and a beta of 0.84. The stock’s fifty day simple moving average is $47.31 and its 200-day simple moving average is $51.35.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). The company had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.42 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.